What is the P/E ratio of Zhejiang Hisun Pharmaceutical Co 2024?
The Zhejiang Hisun Pharmaceutical Co P/E ratio is 17.55.
Own the gold standard ✨ in financial data & analytics
Subscribe for $2 
Overview
Profile
Zhejiang Hisun Pharmaceutical Co Stock stock price, forecast, news, chart, split, dividend and analysis Zhejiang Hisun Pharmaceutical Co ariva, Zhejiang Hisun Pharmaceutical Co onvista, Zhejiang Hisun Pharmaceutical Co finanzen.net, Zhejiang Hisun Pharmaceutical Co aktienfinder, Zhejiang Hisun Pharmaceutical Co marketscreener, Zhejiang Hisun Pharmaceutical Co marketwatch, Zhejiang Hisun Pharmaceutical Co bloomberg, Zhejiang Hisun Pharmaceutical Co handelsblatt, Zhejiang Hisun Pharmaceutical Co wiwo, Zhejiang Hisun Pharmaceutical Co forum
600267.SS
CNE0000013Z2
Price
Price
6.95
Today +/-
+0
Today %
+0 %
Ticker600267.SS
ISINCNE0000013Z2
P
Zhejiang Hisun Pharmaceutical Co Revenue, EBIT, Net Income CNE0000013Z2 ·
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Zhejiang Hisun Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zhejiang Hisun Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zhejiang Hisun Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Zhejiang Hisun Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Zhejiang Hisun Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Zhejiang Hisun Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zhejiang Hisun Pharmaceutical Co’s growth potential.
Zhejiang Hisun Pharmaceutical Co Revenue, EBIT and net profit per share
| Date | Zhejiang Hisun Pharmaceutical Co Revenue | Zhejiang Hisun Pharmaceutical Co EBIT | Zhejiang Hisun Pharmaceutical Co Net Income |
|---|---|---|---|
| 2026e | 11.06 B undefined | 1.38 B undefined | 508.59 M undefined |
| 2025e | 10.79 B undefined | 1.29 B undefined | 473.11 M undefined |
| 2024e | 10.32 B undefined | 1.19 B undefined | 461.28 M undefined |
| 2023 | 10.37 B undefined | 385.6 M undefined | -93.17 M undefined |
| 2022 | 12.04 B undefined | 1.05 B undefined | 489.05 M undefined |
| 2021 | 12.14 B undefined | 964.91 M undefined | 486.89 M undefined |
| 2020 | 11.35 B undefined | 1.12 B undefined | 417 M undefined |
| 2019 | 11.07 B undefined | -391 M undefined | 93 M undefined |
| 2018 | 10.19 B undefined | 316 M undefined | -492 M undefined |
| 2017 | 10.57 B undefined | 552 M undefined | 14 M undefined |
| 2016 | 9.73 B undefined | 223 M undefined | -94 M undefined |
| 2015 | 8.77 B undefined | 158 M undefined | 14 M undefined |
| 2014 | 10.1 B undefined | 789 M undefined | 308 M undefined |
| 2013 | 8.6 B undefined | 685 M undefined | 302 M undefined |
| 2012 | 5.8 B undefined | 300 M undefined | 301 M undefined |
| 2011 | 5.16 B undefined | 599 M undefined | 504 M undefined |
| 2010 | 4.55 B undefined | 445 M undefined | 366 M undefined |
| 2009 | 4 B undefined | 420 M undefined | 272 M undefined |
| 2008 | 3.18 B undefined | 323 M undefined | 195 M undefined |
| 2007 | 2.84 B undefined | 265 M undefined | 140 M undefined |
| 2006 | 2.31 B undefined | 165 M undefined | 82 M undefined |
| 2005 | 1.91 B undefined | 206 M undefined | 116 M undefined |
| 2004 | 1.78 B undefined | 329 M undefined | 204 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 1.78 B CNY | 329 M CNY | 204 M CNY |
| 2005 | 1.91 B CNY | 206 M CNY | 116 M CNY |
| 2006 | 2.31 B CNY | 165 M CNY | 82 M CNY |
| 2007 | 2.84 B CNY | 265 M CNY | 140 M CNY |
| 2008 | 3.18 B CNY | 323 M CNY | 195 M CNY |
| 2009 | 4 B CNY | 420 M CNY | 272 M CNY |
| 2010 | 4.55 B CNY | 445 M CNY | 366 M CNY |
| 2011 | 5.16 B CNY | 599 M CNY | 504 M CNY |
| 2012 | 5.8 B CNY | 300 M CNY | 301 M CNY |
| 2013 | 8.6 B CNY | 685 M CNY | 302 M CNY |
| 2014 | 10.1 B CNY | 789 M CNY | 308 M CNY |
| 2015 | 8.77 B CNY | 158 M CNY | 14 M CNY |
| 2016 | 9.73 B CNY | 223 M CNY | -94 M CNY |
| 2017 | 10.57 B CNY | 552 M CNY | 14 M CNY |
| 2018 | 10.19 B CNY | 316 M CNY | -492 M CNY |
| 2019 | 11.07 B CNY | -391 M CNY | 93 M CNY |
| 2020 | 11.35 B CNY | 1.12 B CNY | 417 M CNY |
| 2021 | 12.14 B CNY | 964.91 M CNY | 486.89 M CNY |
| 2022 | 12.04 B CNY | 1.05 B CNY | 489.05 M CNY |
| 2023 | 10.37 B CNY | 385.6 M CNY | -93.17 M CNY |
| 2024e | 10.32 B CNY | 1.19 B CNY | 461.28 M CNY |
| 2025e | 10.79 B CNY | 1.29 B CNY | 473.11 M CNY |
| 2026e | 11.06 B CNY | 1.38 B CNY | 508.59 M CNY |
Zhejiang Hisun Pharmaceutical Co Stock Ratios
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.36 | 0.52 | 0.58 | 0.76 | 1.55 | 1.78 | 1.91 | 2.31 | 2.84 | 3.18 | 4 | 4.55 | 5.16 | 5.8 | 8.6 | 10.1 | 8.77 | 9.73 | 10.57 | 10.19 | 11.07 | 11.35 | 12.14 | 12.04 | 10.37 | 10.32 | 10.79 | 11.06 |
| - | 44.69 | 11.20 | 32.29 | 103.54 | 14.76 | 7.08 | 21.30 | 22.79 | 12.08 | 25.80 | 13.54 | 13.55 | 12.42 | 48.29 | 17.35 | -13.17 | 11.02 | 8.62 | -3.64 | 8.69 | 2.55 | 6.89 | -0.82 | -13.82 | -0.55 | 4.60 | 2.45 |
| 47.77 | 39.96 | 33.85 | 33.99 | 42.94 | 37.42 | 26.60 | 22.36 | 25.15 | 27.59 | 27.08 | 28.69 | 27.69 | 24.59 | 34.33 | 33.11 | 27.48 | 26.90 | 30.86 | 41.07 | 40.05 | 42.61 | 39.90 | 41.05 | 39.19 | - | - | - |
| 0.17 | 0.21 | 0.2 | 0.26 | 0.67 | 0.67 | 0.51 | 0.52 | 0.71 | 0.88 | 1.08 | 1.3 | 1.43 | 1.43 | 2.95 | 3.34 | 2.41 | 2.62 | 3.26 | 4.18 | 4.43 | 4.84 | 4.84 | 4.94 | 4.07 | 0 | 0 | 0 |
| 0.07 | 0.07 | 0.06 | 0.09 | 0.27 | 0.33 | 0.21 | 0.17 | 0.27 | 0.32 | 0.42 | 0.45 | 0.6 | 0.3 | 0.69 | 0.79 | 0.16 | 0.22 | 0.55 | 0.32 | -0.39 | 1.12 | 0.96 | 1.05 | 0.39 | 1.19 | 1.29 | 1.38 |
| 18.99 | 14.29 | 11.11 | 11.42 | 17.54 | 18.48 | 10.81 | 7.14 | 9.33 | 10.15 | 10.49 | 9.79 | 11.61 | 5.17 | 7.96 | 7.81 | 1.80 | 2.29 | 5.22 | 3.10 | -3.53 | 9.83 | 7.94 | 8.69 | 3.71 | 11.50 | 11.95 | 12.50 |
| 49 | 51 | 49 | 50 | 170 | 204 | 116 | 82 | 140 | 195 | 272 | 366 | 504 | 301 | 302 | 308 | 14 | -94 | 14 | -492 | 93 | 417 | 486 | 489 | -93 | 461 | 473 | 508 |
| - | 4.08 | -3.92 | 2.04 | 240.00 | 20.00 | -43.14 | -29.31 | 70.73 | 39.29 | 39.49 | 34.56 | 37.70 | -40.28 | 0.33 | 1.99 | -95.45 | -771.43 | -114.89 | -3,614.29 | -118.90 | 348.39 | 16.55 | 0.62 | -119.02 | -595.70 | 2.60 | 7.40 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 0.54 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.77 | 0.82 | 0.84 | 0.84 | 0.88 | 0.97 | 0.97 | 0.97 | 0.97 | 0.97 | 0.97 | 1.13 | 1.14 | 1.16 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Zhejiang Hisun Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zhejiang Hisun Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Zhejiang Hisun Pharmaceutical Co stock margins CNE0000013Z2 ·
The Zhejiang Hisun Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zhejiang Hisun Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zhejiang Hisun Pharmaceutical Co.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Zhejiang Hisun Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Zhejiang Hisun Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Zhejiang Hisun Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Zhejiang Hisun Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zhejiang Hisun Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zhejiang Hisun Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zhejiang Hisun Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Zhejiang Hisun Pharmaceutical Co Margin History
| Zhejiang Hisun Pharmaceutical Co Gross margin | Zhejiang Hisun Pharmaceutical Co Profit margin | Zhejiang Hisun Pharmaceutical Co EBIT margin | Zhejiang Hisun Pharmaceutical Co Profit margin |
|---|---|---|---|
| 2026e | 39.2 % | 12.5 % | 4.6 % |
| 2025e | 39.2 % | 11.95 % | 4.38 % |
| 2024e | 39.2 % | 11.5 % | 4.47 % |
| 2023 | 39.2 % | 3.72 % | -0.9 % |
| 2022 | 41.05 % | 8.69 % | 4.06 % |
| 2021 | 39.9 % | 7.95 % | 4.01 % |
| 2020 | 42.61 % | 9.83 % | 3.67 % |
| 2019 | 40.05 % | -3.53 % | 0.84 % |
| 2018 | 41.07 % | 3.1 % | -4.83 % |
| 2017 | 30.86 % | 5.22 % | 0.13 % |
| 2016 | 26.9 % | 2.29 % | -0.97 % |
| 2015 | 27.48 % | 1.8 % | 0.16 % |
| 2014 | 33.11 % | 7.81 % | 3.05 % |
| 2013 | 34.33 % | 7.96 % | 3.51 % |
| 2012 | 24.59 % | 5.17 % | 5.19 % |
| 2011 | 27.69 % | 11.61 % | 9.77 % |
| 2010 | 28.69 % | 9.79 % | 8.05 % |
| 2009 | 27.08 % | 10.49 % | 6.79 % |
| 2008 | 27.59 % | 10.15 % | 6.13 % |
| 2007 | 25.15 % | 9.33 % | 4.93 % |
| 2006 | 22.36 % | 7.14 % | 3.55 % |
| 2005 | 26.6 % | 10.81 % | 6.09 % |
| 2004 | 37.42 % | 18.48 % | 11.46 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 37.42 % | 18.48 % | 11.46 % |
| 2005 | 26.6 % | 10.81 % | 6.09 % |
| 2006 | 22.36 % | 7.14 % | 3.55 % |
| 2007 | 25.15 % | 9.33 % | 4.93 % |
| 2008 | 27.59 % | 10.15 % | 6.13 % |
| 2009 | 27.08 % | 10.49 % | 6.79 % |
| 2010 | 28.69 % | 9.79 % | 8.05 % |
| 2011 | 27.69 % | 11.61 % | 9.77 % |
| 2012 | 24.59 % | 5.17 % | 5.19 % |
| 2013 | 34.33 % | 7.96 % | 3.51 % |
| 2014 | 33.11 % | 7.81 % | 3.05 % |
| 2015 | 27.48 % | 1.8 % | 0.16 % |
| 2016 | 26.9 % | 2.29 % | -0.97 % |
| 2017 | 30.86 % | 5.22 % | 0.13 % |
| 2018 | 41.07 % | 3.1 % | -4.83 % |
| 2019 | 40.05 % | -3.53 % | 0.84 % |
| 2020 | 42.61 % | 9.83 % | 3.67 % |
| 2021 | 39.9 % | 7.95 % | 4.01 % |
| 2022 | 41.05 % | 8.69 % | 4.06 % |
| 2023 | 39.2 % | 3.72 % | -0.9 % |
| 2024e | 39.2 % | 11.5 % | 4.47 % |
| 2025e | 39.2 % | 11.95 % | 4.38 % |
| 2026e | 39.2 % | 12.5 % | 4.6 % |
Zhejiang Hisun Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share CNE0000013Z2 ·
The Zhejiang Hisun Pharmaceutical Co earnings per share therefore indicates how much revenue Zhejiang Hisun Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Zhejiang Hisun Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Zhejiang Hisun Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Zhejiang Hisun Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zhejiang Hisun Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Zhejiang Hisun Pharmaceutical Co Revenue, EBIT and net profit per share
| Date | Zhejiang Hisun Pharmaceutical Co Sales per Share | Zhejiang Hisun Pharmaceutical Co EBIT per share | Zhejiang Hisun Pharmaceutical Co Earnings per Share |
|---|---|---|---|
| 2026e | 9.44 undefined | 0 undefined | 0.43 undefined |
| 2025e | 9.21 undefined | 0 undefined | 0.4 undefined |
| 2024e | 8.81 undefined | 0 undefined | 0.39 undefined |
| 2023 | 8.91 undefined | 0.33 undefined | -0.08 undefined |
| 2022 | 10.54 undefined | 0.92 undefined | 0.43 undefined |
| 2021 | 10.72 undefined | 0.85 undefined | 0.43 undefined |
| 2020 | 11.75 undefined | 1.16 undefined | 0.43 undefined |
| 2019 | 11.46 undefined | -0.4 undefined | 0.1 undefined |
| 2018 | 10.55 undefined | 0.33 undefined | -0.51 undefined |
| 2017 | 10.94 undefined | 0.57 undefined | 0.01 undefined |
| 2016 | 10.08 undefined | 0.23 undefined | -0.1 undefined |
| 2015 | 9.08 undefined | 0.16 undefined | 0.01 undefined |
| 2014 | 11.47 undefined | 0.9 undefined | 0.35 undefined |
| 2013 | 10.24 undefined | 0.82 undefined | 0.36 undefined |
| 2012 | 6.91 undefined | 0.36 undefined | 0.36 undefined |
| 2011 | 6.27 undefined | 0.73 undefined | 0.61 undefined |
| 2010 | 5.87 undefined | 0.57 undefined | 0.47 undefined |
| 2009 | 5.54 undefined | 0.58 undefined | 0.38 undefined |
| 2008 | 4.43 undefined | 0.45 undefined | 0.27 undefined |
| 2007 | 3.95 undefined | 0.37 undefined | 0.19 undefined |
| 2006 | 3.22 undefined | 0.23 undefined | 0.11 undefined |
| 2005 | 2.65 undefined | 0.29 undefined | 0.16 undefined |
| 2004 | 2.48 undefined | 0.46 undefined | 0.28 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2004 | 2.48 CNY | 0.46 CNY | 0.28 CNY |
| 2005 | 2.65 CNY | 0.29 CNY | 0.16 CNY |
| 2006 | 3.22 CNY | 0.23 CNY | 0.11 CNY |
| 2007 | 3.95 CNY | 0.37 CNY | 0.19 CNY |
| 2008 | 4.43 CNY | 0.45 CNY | 0.27 CNY |
| 2009 | 5.54 CNY | 0.58 CNY | 0.38 CNY |
| 2010 | 5.87 CNY | 0.57 CNY | 0.47 CNY |
| 2011 | 6.27 CNY | 0.73 CNY | 0.61 CNY |
| 2012 | 6.91 CNY | 0.36 CNY | 0.36 CNY |
| 2013 | 10.24 CNY | 0.82 CNY | 0.36 CNY |
| 2014 | 11.47 CNY | 0.9 CNY | 0.35 CNY |
| 2015 | 9.08 CNY | 0.16 CNY | 0.01 CNY |
| 2016 | 10.08 CNY | 0.23 CNY | -0.1 CNY |
| 2017 | 10.94 CNY | 0.57 CNY | 0.01 CNY |
| 2018 | 10.55 CNY | 0.33 CNY | -0.51 CNY |
| 2019 | 11.46 CNY | -0.4 CNY | 0.1 CNY |
| 2020 | 11.75 CNY | 1.16 CNY | 0.43 CNY |
| 2021 | 10.72 CNY | 0.85 CNY | 0.43 CNY |
| 2022 | 10.54 CNY | 0.92 CNY | 0.43 CNY |
| 2023 | 8.91 CNY | 0.33 CNY | -0.08 CNY |
| 2024e | 8.81 CNY | 0 CNY | 0.39 CNY |
| 2025e | 9.21 CNY | 0 CNY | 0.4 CNY |
| 2026e | 9.44 CNY | 0 CNY | 0.43 CNY |
Zhejiang Hisun Pharmaceutical Co business model
Zhejiang Hisun Pharmaceutical Co is one of the most popular companies on Eulerpool.com.
Zhejiang Hisun Pharmaceutical Co valuation based on historical P/E ratio, EBIT, and P/S ratio.
Zhejiang Hisun Pharmaceutical Co shares outstanding CNE0000013Z2 ·
The number of shares was Zhejiang Hisun Pharmaceutical Co in 2023 — This indicates how many shares 1.165 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Zhejiang Hisun Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Zhejiang Hisun Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Zhejiang Hisun Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zhejiang Hisun Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 719 M Aktien |
| 2005 | 719 M Aktien |
| 2006 | 719 M Aktien |
| 2007 | 719 M Aktien |
| 2008 | 719 M Aktien |
| 2009 | 723 M Aktien |
| 2010 | 774 M Aktien |
| 2011 | 823 M Aktien |
| 2012 | 840 M Aktien |
| 2013 | 840 M Aktien |
| 2014 | 880 M Aktien |
| 2015 | 966 M Aktien |
| 2016 | 966 M Aktien |
| 2017 | 966 M Aktien |
| 2018 | 966 M Aktien |
| 2019 | 966 M Aktien |
| 2020 | 966 M Aktien |
| 2021 | 1.13 B Aktien |
| 2022 | 1.14 B Aktien |
| 2023 | 1.16 B Aktien |
| 2024e | 1.16 B Aktien |
| 2025e | 1.16 B Aktien |
| 2026e | 1.16 B Aktien |
Zhejiang Hisun Pharmaceutical Co Stock splits
In Zhejiang Hisun Pharmaceutical Co's history, there have been no stock splits.
Zhejiang Hisun Pharmaceutical Co Stock Dividend CNE0000013Z2 ·
In 2023, Zhejiang Hisun Pharmaceutical Co paid a dividend amounting to 0.17 CNY. Dividend means that Zhejiang Hisun Pharmaceutical Co distributes a portion of its profits to its owners.
3 years
5 years
10 years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Zhejiang Hisun Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Zhejiang Hisun Pharmaceutical Co’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Zhejiang Hisun Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Zhejiang Hisun Pharmaceutical Co Dividend History
| Date | Zhejiang Hisun Pharmaceutical Co Dividend |
|---|---|
| 2026e | 0.18 undefined |
| 2025e | 0.18 undefined |
| 2024e | 0.18 undefined |
| 2023 | 0.17 undefined |
| 2022 | 0.14 undefined |
| 2021 | 0.05 undefined |
| 2020 | 0.05 undefined |
| 2018 | 0.05 undefined |
| 2017 | 0.05 undefined |
| 2016 | 0.07 undefined |
| 2015 | 0.11 undefined |
| 2014 | 0.11 undefined |
| 2013 | 0.11 undefined |
| 2012 | 0.09 undefined |
| 2011 | 0.09 undefined |
| 2010 | 0.08 undefined |
| 2009 | 0.06 undefined |
| 2008 | 0.06 undefined |
| 2007 | 0.06 undefined |
| 2006 | 0.06 undefined |
| 2005 | 0.09 undefined |
| 2004 | 0.05 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2004 | 0.05 CNY | 0 CNY |
| 2005 | 0.09 CNY | 0 CNY |
| 2006 | 0.06 CNY | 0 CNY |
| 2007 | 0.06 CNY | 0 CNY |
| 2008 | 0.06 CNY | 0 CNY |
| 2009 | 0.06 CNY | 0 CNY |
| 2010 | 0.08 CNY | 0 CNY |
| 2011 | 0.09 CNY | 0 CNY |
| 2012 | 0.09 CNY | 0 CNY |
| 2013 | 0.11 CNY | 0 CNY |
| 2014 | 0.11 CNY | 0 CNY |
| 2015 | 0.11 CNY | 0 CNY |
| 2016 | 0.07 CNY | 0 CNY |
| 2017 | 0.05 CNY | 0 CNY |
| 2018 | 0.05 CNY | 0 CNY |
| 2019 | 0 CNY | 0 CNY |
| 2020 | 0.05 CNY | 0 CNY |
| 2021 | 0.05 CNY | 0 CNY |
| 2022 | 0.14 CNY | 0 CNY |
| 2023 | 0.17 CNY | 0 CNY |
| 2024e | 0 CNY | 0.18 CNY |
| 2025e | 0 CNY | 0.18 CNY |
| 2026e | 0 CNY | 0.18 CNY |
Zhejiang Hisun Pharmaceutical Co Stock Payout Ratio CNE0000013Z2 ·
In 2023, Zhejiang Hisun Pharmaceutical Co had a payout ratio of 18.62%. The payout ratio indicates the percentage of the company's profits that Zhejiang Hisun Pharmaceutical Co distributes as dividends.
3 years
5 years
10 years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Zhejiang Hisun Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Zhejiang Hisun Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Zhejiang Hisun Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Zhejiang Hisun Pharmaceutical Co Payout Ratio History
| Date | Zhejiang Hisun Pharmaceutical Co Payout ratio |
|---|---|
| 2026e | 21.22 % |
| 2025e | 24.1 % |
| 2024e | 20.96 % |
| 2023 | 18.62 % |
| 2022 | 32.71 % |
| 2021 | 11.53 % |
| 2020 | 11.63 % |
| 2019 | 18.62 % |
| 2018 | -9.8 % |
| 2017 | 500 % |
| 2016 | -70 % |
| 2015 | 1,100 % |
| 2014 | 31.43 % |
| 2013 | 30.56 % |
| 2012 | 26.04 % |
| 2011 | 15.36 % |
| 2010 | 15.96 % |
| 2009 | 16.45 % |
| 2008 | 23.15 % |
| 2007 | 32.89 % |
| 2006 | 56.82 % |
| 2005 | 58.56 % |
| 2004 | 18.61 % |
| Payout ratio | |
|---|---|
| 2004 | 18.61 % |
| 2005 | 58.56 % |
| 2006 | 56.82 % |
| 2007 | 32.89 % |
| 2008 | 23.15 % |
| 2009 | 16.45 % |
| 2010 | 15.96 % |
| 2011 | 15.36 % |
| 2012 | 26.04 % |
| 2013 | 30.56 % |
| 2014 | 31.43 % |
| 2015 | 1,100 % |
| 2016 | -70 % |
| 2017 | 500 % |
| 2018 | -9.8 % |
| 2019 | 18.62 % |
| 2020 | 11.63 % |
| 2021 | 11.53 % |
| 2022 | 32.71 % |
| 2023 | 18.62 % |
| 2024e | 20.96 % |
| 2025e | 24.1 % |
| 2026e | 21.22 % |
Unfortunately, there are currently no price targets and forecasts available for Zhejiang Hisun Pharmaceutical Co.
Zhejiang Hisun Pharmaceutical Co Earnings Surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 3/31/2024 | 0.11 | 0.21 (89.02 %) | 2024 Q1 |
| 12/31/2023 | 0.08 | -0.47 (-681.68 %) | 2023 Q4 |
| 9/30/2023 | 0.21 | 0.03 (-85.78 %) | 2023 Q3 |
| 6/30/2023 | 0.23 | 0.2 (-13.9 %) | 2023 Q2 |
| 12/31/2015 | 0.03 | 0.01 (-68.78 %) | 2015 Q4 |
| 9/30/2015 | 0.07 | -0.03 (-142.43 %) | 2015 Q3 |
| 6/30/2015 | 0.14 | 0.03 (-80.2 %) | 2015 Q2 |
| 12/31/2014 | 0.09 | 0.08 (-11.99 %) | 2014 Q4 |
| 9/30/2014 | 0.09 | 0.07 (-25.19 %) | 2014 Q3 |
| 6/30/2014 | 0.11 | 0.11 (-0.99 %) | 2014 Q2 |
1
2
3
Zhejiang Hisun Pharmaceutical Co Stock Shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 6.21 % | Zhejiang International Business Group Co., Ltd. | 72,673,907 | 0 | 9/30/2023 |
| 5.12 % | Taizhou Jiaojiang District State-owned Capital Operation Group Co Ltd | 59,931,506 | 0 | 9/30/2023 |
| 5.00 % | HPPC Holding SARL | 58,498,791 | -1,894,888 | 9/30/2023 |
| 27.39 % | Zhejiang Hisun Group Co., Ltd. | 320,783,590 | 0 | 9/30/2023 |
| 0.74 % | China Southern Asset Management Co. Ltd. | 8,634,808 | -2,938,000 | 12/31/2023 |
| 0.51 % | Yinhua Fund Management Co., Ltd. | 5,985,362 | 789,900 | 9/30/2023 |
| 0.49 % | Dacheng Fund Management Co., Ltd. | 5,779,200 | 2,914,000 | 9/30/2023 |
| 0.42 % | Peng (Yinsheng) | 4,938,108 | 270,000 | 9/30/2023 |
| 0.35 % | Zhou (Bingji) | 4,131,900 | 0 | 9/30/2023 |
| 0.33 % | Tang (Yue Qing) | 3,830,000 | 3,830,000 | 9/30/2023 |
1
2
3
4
5
...
8
Zhejiang Hisun Pharmaceutical Co Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
| SupplierCustomer | 0,78 | 0,82 | 0,40 | 0,30 | 0,13 | - | |
| SupplierCustomer | 0,46 | -0,25 | -0,43 | -0,32 | -0,18 | - | |
| SupplierCustomer | 0,43 | 0,86 | 0,61 | 0,49 | 0,09 | - | |
| SupplierCustomer | 0,33 | 0,36 | -0,10 | -0,26 | -0,06 | - | |
| SupplierCustomer | 0,22 | 0,88 | 0,75 | 0,63 | 0,54 | - | |
 SVB Financial Group | SupplierCustomer | 0,11 | -0,81 | 0,25 | 0,11 | -0,25 | - |
| SupplierCustomer | -0,45 | -0,82 | -0,37 | 0,02 | 0,08 | - | |
| SupplierCustomer | -0,56 | 0,27 | -0,07 | -0,01 | 0,10 | - | |
| SupplierCustomer | -0,64 | -0,21 | -0,50 | -0,33 | -0,09 | - | |
| SupplierCustomer | -0,75 | -0,81 | 0,56 | 0,22 | -0,08 | - |
1
Zhejiang Hisun Pharmaceutical Co stock: Frequently Asked Questions
What is the P/S ratio of Zhejiang Hisun Pharmaceutical Co 2024?
The Zhejiang Hisun Pharmaceutical Co P/S ratio is 0.78.
What is the AlleAktien quality score of Zhejiang Hisun Pharmaceutical Co?
The AlleAktien quality score cannot be calculated for Zhejiang Hisun Pharmaceutical Co at the moment.
What is the revenue of Zhejiang Hisun Pharmaceutical Co 2024?
The expected Zhejiang Hisun Pharmaceutical Co revenue is 10.32 B CNY.
How high is the profit of Zhejiang Hisun Pharmaceutical Co 2024?
The expected Zhejiang Hisun Pharmaceutical Co profit is 461.28 M CNY.
What is the business model of Zhejiang Hisun Pharmaceutical Co
No history available for Zhejiang Hisun Pharmaceutical Co.
What is the Zhejiang Hisun Pharmaceutical Co dividend?
Zhejiang Hisun Pharmaceutical Co pays a dividend of 0.14 CNY distributed over payouts per year.
How often does Zhejiang Hisun Pharmaceutical Co pay dividends?
The dividend cannot currently be calculated for Zhejiang Hisun Pharmaceutical Co or the company does not pay out a dividend.
What is the Zhejiang Hisun Pharmaceutical Co ISIN?
The ISIN of Zhejiang Hisun Pharmaceutical Co is CNE0000013Z2.
What is the Zhejiang Hisun Pharmaceutical Co ticker?
The ticker of Zhejiang Hisun Pharmaceutical Co is 600267.SS.
How much dividend does Zhejiang Hisun Pharmaceutical Co pay?
Over the past 12 months, Zhejiang Hisun Pharmaceutical Co paid a dividend of 0.17 CNY . This corresponds to a dividend yield of about 2.45 %. For the coming 12 months, Zhejiang Hisun Pharmaceutical Co is expected to pay a dividend of 0.18 CNY.
What is the dividend yield of Zhejiang Hisun Pharmaceutical Co?
The current dividend yield of Zhejiang Hisun Pharmaceutical Co is 2.45 %.
When does Zhejiang Hisun Pharmaceutical Co pay dividends?
Zhejiang Hisun Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, July, June, June.
How secure is the dividend of Zhejiang Hisun Pharmaceutical Co?
Zhejiang Hisun Pharmaceutical Co paid dividends every year for the past 7 years.
What is the dividend of Zhejiang Hisun Pharmaceutical Co?
For the upcoming 12 months, dividends amounting to 0.18 CNY are expected. This corresponds to a dividend yield of 2.56 %.
In which sector is Zhejiang Hisun Pharmaceutical Co located?
Zhejiang Hisun Pharmaceutical Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Zhejiang Hisun Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Zhejiang Hisun Pharmaceutical Co from 5/19/2023 amounting to 0.17 CNY, you needed to have the stock in your portfolio before the ex-date on 5/19/2023.
When did Zhejiang Hisun Pharmaceutical Co pay the last dividend?
The last dividend was paid out on 5/19/2023.
What was the dividend of Zhejiang Hisun Pharmaceutical Co in the year 2023?
In the year 2023, Zhejiang Hisun Pharmaceutical Co distributed 0.14 CNY as dividends.
In which currency does Zhejiang Hisun Pharmaceutical Co pay out the dividend?
The dividends of Zhejiang Hisun Pharmaceutical Co are distributed in CNY.
Zhejiang Hisun Pharmaceutical Co stock price, news, forecast, analysis
Sector
Health
Industry
Pharmaceuticals
Number of shares
Employee
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
People's Republic of China 🇨🇳
Currency
CNY
Initial public offering
Jul 25, 2000
GOSIN
Global Open Securities Identification Number
Cusip
Y9891W105
Market capitalization
PEG
-26.26
P/E
Forward P/E
17.64
P/S
Forward P/S
0.75
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC
-1.82 %
Dividend
Dividend yield
2.45 %
Dividend growth Ø5Y
—
Dividends per year
Paid since
4 years
Not cut since
2 years
Increased since
2 years
Dividends tax
25.83 %
Scalable Capital savings plan Nein
Trade Republic savings plan Nein
comdirect savings plan
Consorsbank savings plan Nein
ING savings plan Nein
Zhejiang Hisun Pharmaceutical Co Peer Group
Zhejiang Hisun Pharmaceutical Co Eulerpool News
Zhejiang Hisun Pharmaceutical Co News
Zhejiang Hisun Pharmaceutical Co Ticker
| Stock Exchange | Zhejiang Hisun Pharmaceutical Co Ticker |
|---|---|
| SHH | 600267.SS |
Zhejiang Hisun Pharmaceutical Co FIGI
| Zhejiang Hisun Pharmaceutical Co Ticker | Zhejiang Hisun Pharmaceutical Co FIGI |
|---|---|
| 600267:CH | BBG000BFPH80 |
| 600267:CG | BBG000BFPHL5 |
| 600267:C1 | BBG00709HKS1 |
Other fundamentals and analyses of Zhejiang Hisun Pharmaceutical Co in the deep dive.
Our stock analysis for Zhejiang Hisun Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zhejiang Hisun Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Zhejiang Hisun Pharmaceutical Co Revenue
- Zhejiang Hisun Pharmaceutical Co Net Income
- Zhejiang Hisun Pharmaceutical Co P/E
- Zhejiang Hisun Pharmaceutical Co P/S
- Zhejiang Hisun Pharmaceutical Co EBIT
- Zhejiang Hisun Pharmaceutical Co Dividend
- Zhejiang Hisun Pharmaceutical Co Stocks
- Zhejiang Hisun Pharmaceutical Co Market capitalization
- Zhejiang Hisun Pharmaceutical Co Debt
- Zhejiang Hisun Pharmaceutical Co Liabilities
- Zhejiang Hisun Pharmaceutical Co Equity
- Zhejiang Hisun Pharmaceutical Co AAQS
- Zhejiang Hisun Pharmaceutical Co Employees
- Zhejiang Hisun Pharmaceutical Co ROE
- Zhejiang Hisun Pharmaceutical Co ROA
- Zhejiang Hisun Pharmaceutical Co ROCE